文献速递湿疹皮炎与荨麻疹

中国特应性皮炎患者的血清生物标志物内型及度普利尤单抗疗效预测

Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
PubMed 文献 · Br J Dermatol · 2023-01-01

研究分析了125例中重度特应性皮炎患者和60例正常对照的24种细胞因子/趋化因子,识别出两种炎症相关内型;度普利尤单抗治疗16周后,基线CD25/sIL-2Rα、IL-31和IL-36β水平可能预测良好疗效。

要点

  • 中国中重度特应性皮炎患者以Th2型血清生物标志物为主,混合Th1、Th17、Th22型细胞因子/趋化因子升高。
  • Th2型血清生物标志物与疾病严重程度和嗜酸性粒细胞计数呈正相关。
  • 基线CD25/sIL-2Rα、IL-31和IL-36β高水平可能预测度普利尤单抗治疗良好疗效。

核心结论

  • 基于血清生物标志物揭示中国特应性皮炎患者存在两种炎症相关内型;高水平的CD25/sIL-2Rα、IL-31和IL-36β可能预测度普利尤单抗治疗的良好疗效。

研究设计与样本

  • 研究纳入125例中重度特应性皮炎患者和60例正常对照,采用磁性Luminex法检测24种细胞因子/趋化因子。
  • 患者接受16周度普利尤单抗治疗,评估疗效并检测血嗜酸性粒细胞、血清IgE和生物标志物。

主要发现

  • 中国中重度特应性皮炎患者以Th2型血清生物标志物为主,并混合有Th1、Th17和Th22型细胞因子/趋化因子的差异性升高。
  • Th2型血清生物标志物与疾病严重程度和嗜酸性粒细胞计数呈正相关。
  • 成年(而非青少年或老年)特应性皮炎患者在不同类型炎症中显示出一致且更显著的生物标志物升高。
  • 无监督k-means分析将患者分为两个聚类,两聚类与炎症的关联存在差异。
  • 度普利尤单抗治疗降低了所分析的大部分细胞因子/趋化因子水平。

关键数值与推荐

  • 两个聚类之间度普利尤单抗疗效无差异。
  • 基线CD25/sIL-2Rα、IL-31和IL-36β水平被确定为与疗效相关的预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a highly heterogeneous disease clinically and biologically. Serum biomarkers have been utilized for endotype identification and have the potential to be predictors for treatment. OBJECTIVES: To explore the serum biomarker-based endotypes of Chinese patients with AD and to identify biomarkers for prediction of the efficacy of dupilumab. METHODS: Sera from 125 patients with moderate-to-severe AD and 60 normal controls (NC) were analysed for 24 cytokines/chemokines using the magnetic Luminex assay. After the patients received 16 weeks of dupilumab treatment, the efficacy was evaluated, and blood eosinophils, serum immunoglobulin (Ig) E and biomarkers were measured. RESULTS: Chinese patients with moderate-to-severe AD were characterized by T-helper (Th)2-dominant serum biomarkers that were mixed with differentially increased Th1-, Th17- and Th22-type cytokines/chemokines, and it was mainly Th2-type serum biomarkers that were positively correlated with disease severity and eosinophil counts. Adult (but not adolescent or elderly) patients with AD showed a consistent and more significant increase of biomarkers across different types of inflammation. The patients were grouped into two clusters by unsupervised k-means analysis, which were differentially associated with inflammation. Treatment with dupilumab decreased the levels of most cytokines/chemokines analysed. While there was no difference between the two clusters in the efficacy of dupilumab, baseline levels of CD25/soluble interleukin (sIL)-2Rα, IL-31 and IL-36β were identified as predictive factors associated with the efficacy. CONCLUSIONS: Our study revealed two inflammation-related endotypes of Chinese patients with AD based on serum biomarkers. High levels of CD25/sIL-2Rα, IL-31 and IL-36β might predict good efficacy of dupilumab treatment.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wu Y, Gu C, Wang S, et al. Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab. Br J Dermatol. 2023. PMID: 36756674. doi:10.1093/bjd/ljad032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。